John Corboy, MD, MA
Professor, Neurology

Professional Titles

• Charles Elliot Morris Chair in Neurology
• Executive Vice Chair of Neurology
• Co-Director, Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus
• Director, Neuroimmunology/MS Fellowship

Research Interests

Teaching

Publications

• Alvarez E, Nair KV, Sillau S, Shelton I, Seale R, Selva S, Corboy J, Vollmer TL. Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions. Mult Scler J Exp Transl Clin. 2022 Jan-Mar;8(1):20552173211069359. PubMed PMID: 35024160
• Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go? JAMA Neurol. 2021 Jul 1;78(7):787-788. doi: 10.1001/jamaneurol.2021.0764.PMID: 33871561
• Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Jul 24;55:103170. doi: 10.1016/j.msard.2021.103170. Online ahead of print.PMID: 34364034
• Vollmer BL, Wolf AB, Sillau S, Corboy JR, Alvarez E. Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis. Front Neurol. 2021;12:799138. PubMed PMID: 35145470
• Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Oct;55:103170. PubMed PMID: 34364034
• Piquet AL, Corboy JR, Vollmer TL. Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211019567. PubMed PMID: 34104219
• Corboy JR, Jones EC, Barbano RL, Anderson DC. 2019-2020: A Message From the Editors to Our Reviewers. Neurol Clin Pract. 2021 Feb;11(1):e1-e5. PubMed PMID: 33968478
• Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?. JAMA Neurol. 2021 Jul 1;78(7):787-788. PubMed PMID: 33871561
• Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders.Ann Clin Transl Neurol. 2020 Aug 6. doi: 10.1002/acn3.51136. Online ahead of print. PMID: 32767531
• Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 Aug 6. doi: 10.1002/acn3.51111. Online ahead of print. PMID: 32767538
• Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, Ford C, Weinstock-Guttman B, Bar-Or A, Mientus S, Sienkiewicz D, Zhang Y, Karan R, Tenenbaum N; Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. ASSESS Trial Investigators. JAMA Neurol. 2020 Aug 24:e202950. doi: 10.1001/jamaneurol.2020.2950. Online ahead of print.PMID: 32852530
• Wu Q, Mills EA, Wang Q, Dowling CA, Fisher C, Kirch B, Lundy SK, Fox DA, Mao- Draayer Y. Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis.; AMS04 Study Group.JCI Insight. 2020 Feb 13;5(3). pii: 134251. doi: 10.1172/jci.insight.134251. PMID: 31935197
• Cree BAC, Cutter G, Wolinsky JS, et al SPI2 investigative teams. Safetyand efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2020 Dec;19(12):988-997. doi: 10.1016/S1474-4422(20)30347-1. Epub 2020 Oct 23.PMID: 33222767
• Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, Ford C, Weinstock-Guttman B, Bar-Or A, Mientus S, Sienkiewicz D, Zhang Y, Karan R, Tenenbaum N; Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. ASSESS Trial Investigators. JAMA Neurol. 2020 Aug 24; 78(1):1-13. doi: 10.1001/jamaneurol.2020.2950. Online ahead of print. PMID: 32852530
• Honce JM, Nair KV, Hoyt BD, Seale RA, Sillau S, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Alvarez E. Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front Neurol. 2020 Sep 23;11:1045. doi: 10.3389/fneur.2020.01045. eCollection 2020.PMID: 33071934
• Waid DM, Schreiner T, Vaitaitis G, Carter JR, Corboy JR, Wagner DH Jr. Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. J Neuroimmunol. 2014 Mar 15. [Epub ahead of print] PubMed PMID: 24690203
• Lafosse JM, Mitchell SM, Corboy JR, Filley CM. The nature of verbal memory impairment in multiple sclerosis: a list-learning and meta-analytic study. J Int Neuropsychol Soc. 2013 Oct;19(9):995-1008. PubMed PMID: 24059259
• Mattson DH, Lisak RP, Jones DE, Corboy JR, Larson R, Gronseth G, Getchius TS, Langer-Gould A, Langer-Gould AM, Gronseth GS, Larson R, Getchius TS. The American Academy of Neurology's top five Choosing Wisely recommendations. Neurology. 2013 Sep 10;81(11):1022-3. PubMed PMID: 24019388
• Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Am J Manag Care. 2013 Apr;19(4):278-85. PubMed PMID: 23725360
• Hebert JR, Corboy JR. The association between multiple sclerosis-related fatigue and balance as a function of central sensory integration. Gait Posture. 2013 May;38(1):37-42. PubMed PMID: 23200463

Professional Memberships

• American Neurological Association, Elected Member
• Colorado Society of Clinical Neurologists, 1995-1997 Secretary/Treasurer
• American Academy of Neurology, Fellow 2003